The Latest Breaking News from AbbVie

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

HR professionals are navigating RTO, AI, cultural changes, and divisive virtual cultural issues.

Hunting for value? These three Dividend Aristocrats look cheap by today's valuations.

With AbbVie gearing up to release its third-quarter earnings later this month, analysts expect a marginal decline in earnings.

Looking for reliable yield? These three companies offer ever-increasing dividends and a lifetime of stability.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

By investing in these dividend powerhouses, investors can achieve reliable income, mitigate risk through diversification, and potentially enjoy capital gains.